lower beovu sale estim substanti wake news rare seriou
report medic meet recent despit subsequ nv ep cut
reiter outperform rate nv growth still appear industri averag
new product line-up moder diminish
annual macula societi meet past weekend post market advers event
involv beovu present approxim beovu dose administ
case retin vascul occlus retin vascul
associ signific vision loss beovu label alreadi reflect rate
inflamm rate retin arteri occlus
incid seriou low still process complet
kol check think appropri lean conserv fear could chill
interest prescrib beovu particularli good altern agent
lower beovu sale estim
lower nv ep estim
ep compound-annual-growth-rate
versu previous still compar favor group averag
nv still power new product stori cosentyx psoriasi entresto chf
zolgensma sma adakveo sickl cell diseas mayzent ms ofatumumab ms
inclisiran reduct nv also signific financi flexibl supplement
growth necessari
basic ep exclud amort one-tim item
pleas see page report import disclosur
nv strength outweigh challeng strength includ entresto cosentyx outlook
new product rollout zolgensma mayzent adakveo inclisiran willing consid
value-cr action potenti sandoz share repurchas challeng includ
beovu headwind entresto uncertainti rel pef hf claim recent clinic trial
setback ep growth prospect appear averag
entresto heart failur cosentyx
aimovig lutathera uptak
entresto cosentyx zolgensma
beovu success greater expect
entresto cosentyx zolgensma
beovu meet expect
sandoz continu struggl
novarti global biopharmaceut compani compani two segment
pharmaceut sandoz includ gener pharmaceut biosimilar
compani data cowen compani estim
compani data cowen compani estim
fgn fgn galvu diovan fgn diovan fgn diovan/co-diovan exforg exforg fgn exforg fgn exforg lotrel- matur total cowen
compani data cowen compani estim
glivec fgn fgn gleevec/glivec tasigna tasigna fgn fgn tasigna afinitor/votubia afinitor/votubia fgn fgn afinitor/votubia votrient/patorma votrient/patorma fgn votrient/patorma fgn sandostatin sandostatin fgn fgn sandostatin franchis cowen
compani data cowen compani estim
 cont promacta/revolad promacta/revolad fgn promacta/revolad fgn exjade/jadenu exjade/jadenu fgn fgn exjade/jadenu tykerb tykerb fgn tykerb fgn arzerra arzerra fgn arzerra fgn kymriah cowen
compani data cowen compani estim
 hycamtin hycamtin fgn hycamtin fgn zometa fgn zometa fgn zometa femara fgn fgn femara oncolog total cowen
compani data cowen compani estim
gilenya gilenya fgn lc gilenya fgn fx gilenya total zolgensma ofatumumab mayzent aimovig extavia tegretol cr/xr trilept exelon/patch exelon/patch fgn lc exelon/patch fgn fx exelon/patch total comtan group comtan group fgn lc comtan group fgn fx comtan group total ritalin group ritalin group fgn lc ritalin group fgn fx ritalin group total neurosci matur neurosci total neurosci cowen
compani data cowen compani estim
xolair ultibro seebri respiratori onbrez/arcapta matur respiratori total respiratori dermatolog cosentyx cosentyx fgn lc cosentyx fgn fx cosentyx myfort myfort fgn lc myfort fgn fx myfort total neoral/sandimmun neoral/sandimmun fgn lc neoral/sandimmun fgn fx neoral/sandimmun total ilari certican/zortress cubicin cowen
compani data cowen compani estim
ligalizumab adrifor other iid matur iid total immunolog dermatolog product voltaren/cataflam everolimu stent manf iscalimab tropifexor/cenicriviroc enablex/emselex product matur ogu total beovu lucenti fgn lc lucenti fgn fx lucenti travoprost travoprost fgn lc travoprost fgn fx travoprost total topic olopatadin topic olopatadin fgn lc topic olopatadin fgn fx topic olopatadin total xiidra luxturna total innov medicin sale dermatolog cont cowen
compani data cowen compani estim
cowen compani
market entresto fgn lc entresto fgn mrked eu hypertens hf file japan ch nrdl inhib file hfpef post acut mi nda potentialgalvu inhibitor launch ex-u distribut stop germani nmnm-sirna month sq physician-administ cvot data file us eu patent exp eu nmnm-iga nephropathi membran nephropathi glomerulopathi file imn file nmnm-secondari prevent cv event elev lipid file gener plain form hctz combo launcheddiovan fgn lc diovan fgn exp spain portug brazil eu japan stoppag altitud safeti substanti tarnish prospectsexforg -declin due gener competitionexforg fgn lc exforg fgn data exclus exp litig marketsexforg exforg hct exclus exp xl sale sale ex-u simvastatin gener erod sharelotrelnmnm-shar exclus teva at-risk launch end patent expir patent compoundstot cowen
cowen compani
gist sun launch gener indic gist teva apotex also launchedglivec fgn lc glivec fgn incid greater ex-u gener launchedgleevec/glivec patent expir treatment-fre remiss approv fgn lc tasigna fgn line cml gist studi discontinuedafinitor/votubia competit pressur limit gener expect end fgn lc afinitor/votubia fgn expir januari pedi exclus afinitor/votubia mrcc sega net aml brca gl/lung approv seizur approv eu votrient/patorma rcc advanc soft tissu sarcoma pressur io votrient/patorma fgn lc votrient/patorma fgn rcc advanc soft tissu sarcoma pressur io vegr tyrosin kinas inhibitor approv rcc incyt market ou myelofibrosi myeloprolif polycythemia vera gvhd acute/chron gener unclearsandostatin fgn lc sandostatin fgn formul patent exp one gener expect soonsandostatin franchis soc net pressu lutathera sale two-third ex inhibitor line breast cancer approv us eu ekg requir solid tumor longer develop braf inhibitor metastat adjuv melanoma approv mono combo us mutat mono eu combo approv lung cancer mek inhibitor metastat adjuv melanoma approv mono us/eu mutat combo approv lung cancer cowen
cowen compani
 cont promacta/revolad itp anemia assoc hcv tx promacta/revolad fgn lc promacta/revolad fgn itp anemia assoc hcv tx neg chmp treatment low platelet count fda approv restrict label md aml phase -pasireotid sold oct recordati expir gener launch jadenu gx fgn lc exjade/jadenu fgn expir feb exjadeexjade/jadenu tablet iron overload label expans myelosdysplast syndrom includ new formul tykerb mbc fail adjuv tykerb fgn lc tykerb fgn mbc arzerra approv refractori first line cll relaps approv file late rm arzerra fgn lc arzerra fgn approv refractori move compassion use fulli human mab right remain indicaton acquir nmnm-ph mcrpc file via endocyt acqusit close gep-net indic develop via advanc acceler acquisit close target cell immunotherapi approv pedi aug dlbcl may r/r fl r/r dlbcl file adult file nmnm-alpelisib alpha inhib line advanc postmenopaus bc trial posit approv us tnbc ovarian adv bc nhscc signal transduct inhibitor aggress system mastocytosi aml approv nmnm-crizanlizumab sickl cell diseas approv us file met exon nsclc file us solid tumor nmnm-net taf/mek mbraf melanoma file metastat melanoma file oral deacetylas inhibitor relaps multipl myeloma approv advanc nsclc approv first therapi crizotinib nave approv tough competit landscap cowen
cowen compani
 nmnm-myelodysplast syndrom file aml file cml file longer nmnm-crc rcc file nmnm-multipl solid tumor file hycamtin hycamtin fgn lc hycamtin fgn topotecan refractori sclc first line ovarianzometa fgn lc zometa fgn patent expir nmnmfemara fgn lc femara fgn inhibitor exp gener june eu gener may gsk oncolog acquisit close cowen
cowen compani
gilenya exp includ pedi assum litig extend exclus gilenya fgn lc gilenya fgn fx patent expir japan patent expir gilenya total pedi ms apprv fail ppm zolgensma sma approv file eu approv via avexi acq cash close file type rett syndrom ofatumumab mab relaps multipl sclerosi sq phase ii file prv mayzent nmnm-siponimod modul oral approv us/eu broad ms label cv monitor pt aimovig nmnm-erenumab select cgrp ra migrain sq approv episod chronic migrain co-promot right row ex japan extavia ms/ betaseron agreement bayer launch tegretol cr/xr patent patient unlik switch trilept composit patent expir gener launch exelon/patch launch sdz launch author exelon/patch fgn lc exelon/patch fgn fx exelon/patch total drive growth franchis aricept gener clip oral sale comtan group comtan group fgn lc comtan group fgn fx comtan group total stalevo pd orion stalevo paragraph iv file teva sun comtan exp ritalin group ritalin group fgn lc ritalin group fgn fx ritalin group total ritalin la focalin xr focalin exclus expir patent exp neurosci matur neurosci clozariltot neurosci cowen
cowen compani
xolair asthma roch chronic spontan urticaria nasal polyp review nmnm-laba/steroid combin indacaterol/mometason asthma file ex-u nmnm-laba/ics/lama tripl combin indacaterol mometason glycopyrronium asthma file ex-u ultibro fdc indacaterol/glycopyrronium bromid copd launch germani netherland japan right licens sunovion bid dose seebri qd lama glycopyrronium copd approv japan right licens sunovion bid dose nmnm-sever asthma file nmnm-copd file respiratori onbrez/arcapta laba indacaterol copd approv right licens sunovion matur respiratori respiratori dermatolog cosentyx share competit increas cosentyx fgn lc cosentyx fgn fx eu japan china nrdl cosentyx psoriasi non-radiograph axspa file vs humira miss primari endpt gca myfort myfort fgn lc myfort fgn fx myfort total transplant agent neoral/sandimmun neoral/sandimmun fgn lc neoral/sandimmun fgn fx neoral/sandimmun total row major sale gener substitut minim ilari anti-il beta mab cap approv refractori gout bla cr approv sjia /eu approv period fever syndrom approv eu nsclc adjuv loe us eu certican/zortress approv us kidney/liv approv eu kidney/liver/heart cubicin mrsa antiifect european right cowen
compani data cowen compani estim
ligalizumab anti-ig mab chronic spontaneous/idiopath urticaria file nmnm-chronic spontan urticaria file adrifor atop dermat file nmnm-atop dermat file nmnm-anti-baff primari sjoegren syndrom autoimmun hepat file nmnm-osteoarthr file other iid basiliximab transplant tyzeka hbv matur iid immunolog dermatolog product voltaren/cataflam nsaid still grow ex-u everolimu stent manf abbott muscular atrophi file iscalimab renal/liv transplant file sjorgen syndrom file tropifexor/cenicriviroc fxr agonist non-alcohol steatohepat nash phase ii file collabor enablex/emselex bladder right sold warner chilcott product matur ogu total beovu nmnm-brolucizumab antivegf ab fragment neovascular approv dme rvo/pdr rare could clip usag lucenti fgn lc dme cnv brvo crvo china nrdl lucenti fgn fx lucenti right pat exp off-label avastin use small eylea competit challeng travoprost travoprost fgn lc travoprost fgn fx travoprost total glaucoma topic olopatadin topic olopatadin fgn lc topic olopatadin fgn fx topic olopatadin total antihistamin xiidra nmnm-dri eye acquir takeda mileston close luxturna nmnm-rare inherit retina diseas one-tim gene therapi approv eu spark nmnm-dri eye file nmnm-chronic ocular surfac pain file nmnm-presbyopia file sale alcon restated-tot sale alcon restatedtot competit growth driver innov medicin sale dermatolog cont cowen
compani data cowen compani estim
sale us oral solids/derm sold aurobindo assum close end eu biosimilar approvedrow -lc -includ falcon gener ophthalm biosimilar approvedrow incld biolog binocrit epo airflus gener aspen jp busi acq close novarti sale guidanc top line growth year guidanc mid/high singl cer ex alcon/sandoz cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl gleevec tasigna
galvu gilenya afinitor lucenti success pipelin product success deal
patent litig patent expir pressur notabl gleevec
manufactur issu challeng non-pharma segment
